Black Diamond Therapeutics (BDTX) Enterprise Value (2020 - 2026)

Black Diamond Therapeutics (BDTX) has reported Enterprise Value for 7 consecutive years, with -$4.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 141.81% year-over-year to -$4.2 million; the trailing twelve-month figure through Jun 2026 stood at -$4.2 million (down 141.81% YoY), and the FY2025 full-year result was $10.2 million, down 54.98% from the prior year.
• Enterprise Value declined to -$4.2 million in Q2 2026 per BDTX's latest filing, from $3.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at $151.1 million in Q1 2024 and bottomed at -$82.7 million in Q3 2022.
• Historically, Enterprise Value has averaged $14.3 million across 5 years, with a median of $3.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value plunged 243.58% in 2022, then soared 3283.01% in 2024.
• Over 5 years, Enterprise Value stood at -$57.2 million in 2022, then surged by 123.98% to $13.7 million in 2023, then surged by 65.0% to $22.6 million in 2024, then tumbled by 54.98% to $10.2 million in 2025, then tumbled by 141.5% to -$4.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.2 million, $3.8 million, and $10.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.